Contract research organisation hVIVO plc (AIM:HVO) announced on Monday that it has signed an agreement with clinical-stage biotechnology company Inhalon Biopharma Inc to conduct a Respiratory Syncytial Virus (RSV) human challenge trial.
The Phase 2a trial will assess Inhalon's inhaled antiviral candidate, IN-002, using hVIVO's RSV Human Challenge Model. It will evaluate IN-002's safety, pharmacokinetics and antiviral activity at three dose levels.
hVIVO's FluCamp will recruit healthy volunteers for the study. The trial is expected to begin in the second half of 2026 at hVIVO's Canary Wharf facilities.
Revenue from the contract is primarily expected to be recognised in 2026.
IN-002 uses Inhalon's inhaled drug delivery platform.
OS Therapies secures US patent for OST-HER2 manufacturing, extending exclusivity to 2040
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
Kexing Biopharm's GB05 IND application receives US FDA approval
AroCell secures Chinese patent for respiratory infection detection
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline
Henlius's serplulimab approved in Europe for Extensive-Stage Small Cell Lung Cancer
Polarean Imaging expands reach with Taiwanese distribution deal
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer
hVIVO to conduct RSV human challenge trial for Inhalon Biopharma